glp-1 receptor agonists mechanism of action GLP1 GLP-1 Receptor Agonists as Treatments

Sources of uncertainty originate from the panoply of glycemic targets, the complexity of drug therapy, the choice of the first drug, the ideal sequence of drugs after the first drug failure, the possible harms of anti-hyperglycemic drugs, the outcomes of treatment (surrogate versus clinical) and the hierarchy of risk factors to treat for preventing the vascular complications

Janzen KM, Steuber TD, Nisly SA

doi: 10.1177/1060028017689878 64 Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus

In 1970 the glucagon precursor, proglucagon, was identified

Alternatives and Substitutes Is cost, access, or side effects making Mounjaro or Ozempic challenging

However, given the neutral effect of GLP-1 RAs on surrogate HF outcomes in HFrEF and a potentially increased risk of arrhythmias and HF-related hospitalisations, conducting further large-scale trials in the HFrEF cohort seems complicated